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Effects of two different doses of acetylsalicylic acid on
serum nitric oxide, asymmetric dimethylarginine,
and homocysteine levels in healthy volunteers*
İdris MEHMETOĞLU, Sevil KURBAN
Aim: To examine the effects of ASA on serum nitric oxide (NO), asymmetric dimethylarginine (ADMA), and
homocysteine levels in healthy volunteers.
Materials and methods: Totally, 26 apparently healthy volunteers were enrolled in the study. Of the participants, 13
(5F, 8M) received 100 mg ofASA daily and 13 (5F, 8M) received 150 mg of ASA daily for 2 months. Serum NO, ADMA,
and homocysteine levels were measured before and 1 and 2 months after ASA treatment Serum NO, ADMA, and
homocysteine levels were measured before and 1 and 2 months after ASA treatment.
Results: ADMA levels of the group receiving 150 mg of ASA were significantly reduced after 2 months of treatment (P
< 0.05). NO levels of both groups were slightly but not significantly increased and homocysteine levels of both groups
were slightly reduced after ASA treatment compared to the baseline values.
Conclusion: Our findings indicate that ASA treatment reduces ADMA levels dose and time dependently, a beneficial
effect that may contribute to the prevention of cardiovascular diseases.
Key words: Acetylsalicylic acid, nitric oxide, asymmetric dimethylarginine, homocysteine, healthy volunteers

Farklı iki doz asetilsalisilik asidin sağlıklı gönüllülerde serum nitrik oksit,
asimetrik dimetilarjinin ve homosistein seviyelerine etkileri
Amaç: Bu çalışmanın amacı sağlıklı gönüllülerde ASA’nın serum nitrik oksit (NO), asimetrik dimetilarjinin (ADMA)
ve homosistein seviyelerine etkisini belirlemektir.
Yöntem ve gereç: Çalışmada toplam 26 sağlıklı gönüllü yer aldı. İki ay süresince katılanlardan 13’ü (5K, 8E) günde
100 mg ve 13’ü (5K, 8E) günde 150 mg ASA aldı. ASA tedavisinden önce ve bir ve iki ay sonra serum NO, ADMA
ve homosistein seviyeleri ASA tedavisinden önce ve bir ve iki ay sonra serum NO, ADMA ve homosistein seviyeleri
ölçüldü.
Bulgular: 150 mg ASA kullanan grubun ADMA seviyeleri iki aylık tedavinin sonunda anlamlı olarak azalmıştı (P <
0,05). ASA tedavisinden sonra başlangıç değerleri ile karşılaştırıldığında her iki grubun NO seviyeleri hafif ama önemsiz
artmış homosistein seviyeleri ise hafif azalmıştı.
Sonuç: Bulgularımız ASA tedavisinin ADMA seviyelerini doz ve zamana bağlı olarak azalttığını gösterdi. Bu faydalı etki
kardiovasküler hastalıkların önlenmesine katkıda bulunuyor olabilir.
Anahtar sözcükler: Asetilsalisilik asit, nitrik oksit, asimetrik dimetilarjinin, homosistein, sağlıklı gönüllüler
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Introduction
Acetylsalicylic acid (ASA, aspirin) is a drug with
anti-inflammatory, antithrombotic, and analgesic
therapeutic properties (1). The beneficial effects of
ASA are due mainly to its antiplatelet action, which
prevents the formation of arterial platelet thrombi.
However, other platelet inhibitory agents have not
been found to be effective or as effective as ASA.
Therefore, the discrepancy between the efficacy
of these compounds and ASA suggests that the
therapeutic efficacy of ASA may not be limited only
to its platelet inhibitory effect (2).
Nitric oxide (NO), a critically important signaling
molecule in the cardiovascular system (CVS) (3),
is endowed with important antiatherosclerotic
properties (4). NO is synthesized from L-arginine
by NO synthase (NOS) in endothelial cells (3) and
its effects are mediated by the second messenger
cyclic guanosine monophosphate (cGMP) (3).
An imbalance in the production or bioavailability
of NO, or its downstream signaling molecule,
cGMP, in the vasculature is implicated in the
pathogenesis of endothelial and vascular smooth
muscle dysfunction and is the background
for hypertension, atherosclerosis, and other
cardiovascular disorders (3). In fact, reduced NO
bioavailability may be considered an important risk
factor for atherothrombosis and acute cardiovascular
events (3,4). Accumulating evidence suggests that
ASA may have additional biological properties
on the vasculature that contribute to increased
NO formation and protect the endothelium from
deleterious effects of oxidative stress (5,6) and the
NO/cGMP system assumes a crucial function in
mediating the cytoprotective action of ASA (7).
Asymmetric dimethylarginine (ADMA), a methyl
derivate of the amino acid arginine, can inhibit
NOS in vivo and in vitro (4). ADMA is actively
metabolized by the enzyme dimethylarginine
dimethylaminohydrolase (DDAH) (4). The activity
of DDAH seems to be particularly susceptible to
inhibition by oxidative stress (4,5). Increased plasma
ADMA levels reduce NO synthesis, leading to
endothelial dysfunction and increased cardiovascular
risk and cognitive dysfunction (4,8-10). Elevated
plasma ADMA levels have been reported in
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connection with atherosclerotic diseases such as
hypertension (8) and diabetes mellitus (DM) (11).
Another molecule associated with vascular
disease and atherothrombosis is homocysteine.
Homocysteine increases the damage to the CVS in
different ways; most known forms of damage or injury
are due to homocysteine mediated oxidative stress.
Chief among these are changes in the intracelluler
redox potential, interference with the NO system, and
activation of transcription factors with stimulation of
gene expression (12,13).
Homocysteine has been shown to inhibit
endothelial DDAH enzyme activity, causing the
accumulation of ADMA and the inhibition of NO
synthesis (9,10).
Both homocysteine (12,13) and ADMA (14)
represent novel mediators of oxidative stress. If
ADMA and homocysteine also could play a role in the
pathogenesis of atherosclerosis and cardiovascular
disease (CVD) it must be important to reduce
concentrations of these molecules in preventing
atherosclerosis.
ASA is one of the most potent antioxidant
compounds known (15). However, in addition to
its antithrombotic and anti-inflammatory effects (1)
many details of the ASA action mechanism are not
completely understood. Accordingly, the present
study was performed to examine whether ASA in
different doses (100 and 150 mg daily) affects serum
ADMA, NO, and homocysteine levels in healthy
volunteers.
Materials and methods
Patients
Totally, 26 apparently healthy volunteers were
enrolled in the study. Of the participants, 13 (5F, 8M)
received 100 mg of ASA daily (group I) and 13 (5F,
8M) received 150 mg of ASA daily (group II) for 2
months. Since it has been reported that a daily dosage
of 75 to 150 mg is sufficient to reduce the rate of future
cardiac events (16) and 75 to 325 mg is sufficient
in acute treatment and secondary prevention of
coronary diseases and CVD (6), and major bleeding
has been demonstrated to depend on the dose of ASA
(1), we used 100 and 150 mg of ASA in our study. The
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ASA used (ecopirin®; Abdi İbrahim İlaç San, İstanbul,
Turkey) was enteric coated. The age of the volunteers
ranged from 40 to 53 (45.57 ± 3.98) years for group I
and from 40 to 53 (48.54 ± 4.46) years for group II and
the subjects were not on any medication for known
risk factors for chronic diseases such as CVD, DM,
or hypertension. The study protocol was approved
by the Ethics Committee of Meram Medical School,
University of Selçuk, Konya, Turkey. All volunteers
were informed of the details of the study and written
consent was received from each patient.

(pH 10.0), and 30 μL of 2-mercaptoethanol] and then
injected into the chromatographic system. Separation
of ADMA was achieved with a 150 × 4-mm I.D. Novapak C18 column with a particle size of 5 μm (Waters
Inc., Milford, MA, USA) using 50 mM sodium
acetate (pH 6.8), methanol, and tetrahydrofuran as
mobile phase (A, 82:17:1; B, 22:77:1) at a flow rate of
1.0 mL/min. The area of peak detected by fluorescent
detector (excitation: 338 nm; emission: 425 nm) was
used for quantification of ADMA levels in serum.

Measurement of biochemical parameters

Serum homocysteine levels were measured
using a commercially available kit produced by
Chromsystems for HPLC (Agilent 1100 series
fluorescence detector).

Fasting blood samples of the subjects were drawn for
biochemical analysis before and 1 and 2 months after
ASA treatment. The blood samples were kept at room
temperature for 30 min; then sera were separated
from the cells by centrifugation at 4 °C at 1469 × g for
10 min. Serum samples were stored at −80 °C until
the day of biochemical analysis. Then serum NO,
ADMA, and homocysteine levels were measured.
Measurement of NO levels
Serum NO (nitrate plus nitrite) levels were measured
by the Griess method with a commercially available
kit (Nitrate/Nitrite colorimetric assay kit, Cayman
Chemical Co., cat no: 780001). Briefly, after being
passed through ultrafilters (Millipore, cat no: 42421),
40 mL of the serum was diluted with 240 mL of assay
buffer and mixed with 10 mL of cofactor and 10
mL of nitrate reductase. After the plasma had been
kept at room temperature for 3 h to convert nitrate
to nitrite, total nitrite was measured as serum NO at
540 nm absorbance by reaction with Griess reagent
(sulfanilamide and naphthalene–ethylene diamine
dihydrochloride).
Measurement of ADMA levels
Measurement of ADMA was accomplished by high
performance liquid chromatography (HPLC), using
the method described by Chen et al. (17). In brief,
to 1 mL serum was added 20 mg of 5-sulfosalicylic
acid (5-SSA), and the mixture was left in an ice bath
for 10 min. The precipitated protein was removed by
centrifugation at 2000 × g for 10 min. Ten microliters
of the supernatant, which was filtered through a 0.2 μm
filter, was mixed with 100 μL of derivatization reagent
[prepared by dissolving 10 mg of o-phthaldialdehyde
in 0.5 mL of methanol, 2 mL of 0.4 M borate buffer

Measurement of homocysteine levels

Statistical analysis
Statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS,
Version 16.0). Data are expressed as mean ± standard
error of the mean (SEM). Statistical analysis of data
within and between groups was performed with
repeated measure analysis of variance. In the presence
of significance within the groups individual paired
comparisons were made using the Wilcoxon signed
ranks test or paired t tests with Bonferroni multiple
comparison adjustment. Differences were considered
significant at a probability level of P < 0.05.
Results
Mean ± SEM values of NO, ADMA, and homocysteine
levels before and after treatment are given in the
Table. NO of both groups were slightly but not
significantly increased and homocysteine levels of
both groups were slightly reduced 1 and 2 months
after ASA treatment compared to the baseline values.
Moreover, ADMA levels of the group receiving
100 mg of ASA (group I) were slightly but not
significantly reduced 1 and 2 months after treatment.
However, ADMA levels of the group receiving 150
mg of ASA (group II) were significantly reduced after
2 months of the treatment (P < 0.05).
On the other hand, when the groups were
compared with each other, there were no significant
differences between their results measured before
and after 1 or 2 months of ASA treatment.
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Table. The measured parameters of the groups (mean ± SEM).

Parameters

Groups

Before ASA treatment

One month after ASA
treatment

Two months after
ASA treatment

ADMA
(μmol/L)

Group I

0.63 ± 0.05

0.60 ± 0.05

0.61 ± 0.04

Group II

0.61 ± 0.06

0.59 ± 0.06

0.50 ± 0.05*

NO
(μmol/L)

Group I

23.24 ± 4.16

24.95 ± 3.67

28.22 ± 6.34

Group II

21.99 ± 3.10

22.90 ± 2.95

29.63 ± 5.67

Homocysteine
(μmol/L)

Group I

20.24 ± 6.24

20.01 ± 5.86

17.62 ± 4.59

Group II

22.37 ± 6.98

20.47 ± 7.88

16.48 ± 5.18

*P < 0.05 compared to the value before treatment

Discussion
The present study demonstrates that ASA treatment
significantly decreased serum concentrations of
ADMA in a dose- and time-dependent manner.
We hypothesized that this reduction may have been
due to increased degradation of ADMA by DDAH,
because it has been shown that pharmacological
prevention of the inhibition of DDAH activity can
decrease the accumulation of ADMA (5,9,10).
Increased plasma ADMA levels mainly occur
following inhibition of the enzyme responsible
for ADMA catabolism, DDAH, by oxidative stress
(4,5,18). Therefore, to reduce oxidative stress is
expected to enhance DDAH activity and decrease
plasma ADMA levels (9,10,19).
Probucol, a compound endowed with both
antioxidant properties and lipid lowering effects,
was found to significantly reduce plasma ADMA
concentrations, increase NO levels, and improve
endothelial function in rats with endothelial
dysfunction induced by intravenous injection of LDL
(20).
Since ASA has antioxidative properties, it can
be argued that it preserves DDAH activity, which
results in reduced ADMA level. Indeed, in a
previous study, we found that LDL oxidation was
significantly inhibited and total oxidant status (TOS)
was decreased by ASA treatment, an effect that was
time and dose dependent (21). Deng et al. (22) have
reported that increased ADMA levels in rats treated
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with LDL were decreased and DDAH activity was
increased by ASA. Moreover, aging (5) and high
glucose (23) induced ADMA accumulation, and
increased reactive oxygen species (ROS) levels in
human umbilical vein endothelial cells (HUVECs)
were found to be reduced by ASA dose dependently.
In another study, Hennekens et al. (24) found that,
in patients with metabolic syndrome, ASA in doses
from 81 mg to 1300 mg daily for 12 weeks produced
significant decreases in the NOS inhibitor ADMA.
These findings confirm our finding of reduced
ADMA levels in the 150 mg ASA treated group, after
2 months.
Several mechanisms have been proposed to
underlie the potential role of ASA as an antioxidant.
For example, ASA at low concentrations protects
endothelial cells from the deleterious effects of
iron dependent oxygen radical formation (25).
Furthermore, chronic treatment with ASA markedly
reduced vascular production of superoxide anion
(15). ASA was also reported to show free radical
scavenging properties and protect endothelial cells
from the deleterious effects of hydrogen peroxide
and iron induced toxicity (26).
Taken together, all the above reports show that
ASA has antioxidative properties that could reduce
oxidative stress and enhance DDAH activity, which
results in reduced ADMA levels as found in our study.
On the other hand, ASA itself may activate DDAH
activity, the mechanism of which is not known and
needs to be investigated.
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There is a regulatory feedback mechanism
between DDAH, ADMA, NOS, and NO (4). Indeed,
ADMA is the major endogenous inhibitor of NOS
and increased plasma ADMA levels cause impaired
NO synthesis (4,9,10). In our study, serum NO levels
of the group receiving ASA were slightly but not
significantly increased, whereas homocysteine levels
were decreased. There are some conflicting reports
about the effects of ASA on these parameters. For
example, Bode Böger et al. (5) have reported that
ADMA and ROS levels were significantly increased
and NO levels decreased in HUVECs by aging. Yi et
al. (23) have shown that ASA can protect endothelial
cells from high glucose induced oxidative stress and
senescence by decreasing ADMA accumulation and
upregulating NO production via enhancing NOS
activity. Taubert et al. (6) have demonstrated that
therapeutically relevant concentrations of ASA elicit
NO release from vascular endothelium.
Although the mechanisms of ASA induced
endothelial protection are largely unknown, ASA has
been reported to improve the endothelial functions
by increasing NO level through the cyclooxygenase
independent mechanism (6,7), because ASA was
found to activate the NO-cGMP signaling pathway
in endothelial cells. Thus, it has been suggested that
NO might have a role as a downstream mediator in
ASA dependent endothelial protection (7).
Zhao et al. (27) have shown that 75 mg daily ASA
did not change plasma NO levels in healthy subjects
in 2 weeks. This finding supports our finding of
slightly but not significantly increased NO levels in
our subjects. However, Girish et al. (28) treated 15

breast cancer patients and 15 age-matched controls
with 150 mg daily of ASA and reported that there
was an increase in serum NO levels in the patients
and the normal volunteers. Moreover, Hennekens et
al. (24) have shown that ASA in doses from 81 mg to
1300 mg daily for 12 weeks increased NO formation
in patients with metabolic syndrome. These findings
do not agree with ours. However, the subjects that
participated in the above studies and the time period
of the ASA treatment they used were different from
those in our study. Therefore, we think that possibly
higher doses of ASA for longer time periods are
needed to obtain a significant increase in NO levels
in healthy subjects.
Treatment of mitogen activated human peripheral
blood mononuclear cells (PBMC) with ASA and
salicylic acid was found to inhibit homocysteine
formation dose dependently (29). Although
pretreatment of PBMC with ASA concentrations of
≤1 mmol did not alter homocysteine concentrations,
ASA concentrations of 3 and 5 mmol significantly
reduced homocysteine concentrations (29).
Moreover, people at high risk of dementia receiving
low dose ASA (81 mg) for 12 weeks had decreased
homocysteine concentrations but the changes were
not significant (30).
In conclusion, our findings indicate that 150 mg/
day ASA treatment significantly reduces ADMA
levels related to antioxidant protection of ASA.
Therefore, this effect of ASA may contribute to the
prevention of CVD, a beneficial effect that is dose
and time dependent.
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